PriceSensitive

Creso Pharma (ASX:CPH) advantaged as UN reclassifies cannabis

Health Care
ASX:CPH
03 December 2020 12:45 (AEDT)

Creso Pharma (CPH) is set to benefit from a United Nations decision to withdraw marijuana’s classification as a dangerous Schedule IV substance.

Cannabis will now be classified under Schedule I — the least restrictive drug classification — which the company says is a recognition of the potential medical properties of the drug.

It is anticipated the ruling will create numerous new near term opportunities for Creso.

The vote was cast by the Vienna-based Commission on Narcotic Drugs (CND) on December 2, 2020, after a series of recommendations were put forward by the World Health Organisation (WHO).

The change in classification was also driven by Creso Co-Founder and Director Boaz Wachtel, who is part of the European Coalition for Just and Effective Drug Policies (ENCOD).

Boaz attended a number of UN Drug Convention meetings in Vienna and assisted in preparing research papers that were submitted to the CND ahead of the vote.

He said the announcement is a landmark decision for the industry.

“The result of this vote follows 60 years of status quo, three years of scientific review by the world’s leading health organisations, two years of diplomatic discussions and considerable lobbying from NGOs,” Boaz noted.

“I am very confident that this decision will unlock a number of near term opportunities for Creso Pharma.”

Shares in Creso Pharma are up a health 27 per cent on the back of the announcement, trading at 8 cents each at 9:12 am AEDT.

Related News